Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P990064/S096

Mosaic Bioprosthesis

Medtronic, Inc. · Decision date Feb 12, 2026

FDA DECISIONP990064/S096

What did the FDA approve?

FDA records P990064/S096 as a supplement to PMA P990064, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Feb 12, 2026.

FDA approval order statement

approval for a Pre-Determined Change Control Plan (PCCP) that establishes a standardized qualification process for new bovine and porcine tissue suppliers, provided they do not impact the tissue's specifications, the established methods for its sourcing, handling, and testing, or the qualification standards for supplier facilities and personnel for the devices under the above PMAs
Regulatory pathway
PMA supplement
Supplement type
135 Review Track For 30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Feb 12, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P990064/S096
Regulatory pathway
PMA supplement
Product code
DYE
Decision code
APPR
Decision date
Feb 12, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: replacement Heart-valve.

Product code
DYE
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P990064/S096 received

    Application receipt date recorded by FDA.

  2. P990064/S095 · Related supplement

    Mosaic Bioprosthesis, Models 305, 310

  3. P990064/S096 · FDA decision

    135 Review Track For 30-Day Notice

  4. P990064/S094 · Related supplement

    Mosaic Neo Mitral Bioprosthesis

Timeline entries are records held by MedtechLedger for P990064. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P990064

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA supplementOct 23, 2025FDA
Medtronic, Inc.PMA supplementNov 10, 2025FDA
Medtronic, Inc.PMA supplementMar 3, 2026FDA

Explore the linked device profile

Other records with product code DYE

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
1851 E. Deere Ave., Santa Ana, CA, 92705

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records